Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: A small animal model for humans with high responder inhibitor phenotype

Thrombosis and Haemostasis

Volumn 75, Issue 2, 1996, Pages 318-325

  Jarvis, M A ^a   Levin, L G ^c   Harrison, J A ^a   DePianto, D J ^a   Suzuki, C M ^b   Ziaja, C L ^a   Brown, J E ^d   Jolly, K W ^a   Reisner, H M ^c   Abildgaard, C F ^a   Powell, J S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; DRUG ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; HEMOPHILIA A; IMMUNIZATION; IMMUNOGENICITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 9044240476     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650268     Document Type: Article

References (29)

1. Foster P, Zimmerman T. Factor VIII structure and function. Blood Reviews 1989; 3: 180-91.
2. Lollar P. Structure and function of Factor VIII. In: Inhibitors to Coagulation Factors. Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC, eds. Plenum, New York, NY 1995; pp 3-18.
3. Fulcher CA. Immunochemistry of Factor VIII:C inhibitor antibodies. Am J Med 1991; 91 (5A): 6S-8S.
4. Hoyer LW, Scandella D. Factor VIII inhibitors: Structure and function in autoantibody and hemophilia patients. Semin Hematol 1994; 31 (Suppl 4): 1-5.
5. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J, Hemophilia Study Group. The natural history of factor VIII:C inhibitors in patients with hemophilia A: A national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-8.
6. Allain J-P, Frommel D. Antibodies to factor VIII. V. Patterns of Immune response to factor VIII in Hemophilia A. Blood 1976; 47: 973-82.
7. Bloom AL. Management of FVIII inhibitors: Evolution and current status. Haemostasis 1992; 22: 268-75.
8. Kessler CM. Factor VIII inhibitors: An algorithmic approach to treatment. Semin Hematol 1994; 31 (Suppl 4): 33-6.
9. Mariani G, Scheibel E, Nogao T, Kasper CK, Ewing NP, Mauser-Bunschoten E, Ghirardini A, Bellocco R, Brackman HH. Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols. Semin Hematol 1994; 31 (Suppl 4): 62-4.
10. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia: Principal results from the International Registry. Report of the Factor VIII and IX Subcommittee. Thromb Haemost 1994; 72: 155-8.
11. Ehrenforth S, Kreuz W, Funk M, Auerswald G, Scharrer I. Variables that might affect the outcome of immune tolerance therapy in haemophilia with factor VIII inhibitors. Thromb Haemost 1994; 72: 784-5.
12. Tinlin S, Webster S, Giles, AR. The development of homologous (canine/anti-canine) antibodies in dogs with haemophilia A (factor VIII deficiency): A ten-year longitudinal study. Thromb Haemost 1993; 69: 21-4.
13. Giles AR. Functional, biochemical and morphological evaluations of experimental hemophilia therapies in animal models. Semin Hematol 1994; 31 (Suppl 4): 56-9.
14. Finney M. Molecular cloning of PCR products. Alternate Protocol: Generation of Half-Sites. In: Current Protocols in Molecular Biology, vol 2. Coen DM ed. Wiley and Sons, New York, NY 1994; pp 15.7.3-15.8.8.
15. Laemmli UK. Cleavage of structure protein during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
16. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, Fratantoni J, Green D, Hampton J, Hilgartner M, Levine P, Lazerson J, McMillan C, Penner J, Shapiro S, Shulman NR. Proceedings: A more uniform measurement of factor VIII inhibitors. Thrombos Diathes Haemorr 1975; 35: 869-72.
17. Berzofsky JA, Schechter AN, Kon H. Does Freund's adjuvant denature protein antigens? EPR studies of emulsified hemoglobin. J Immunology 1976; 115: 270-2.
18. Smith JA, Hurrell JGR, Leach SJ. Conformational integrity of myoglobin after immunization with Freund's adjuvant. J Immunol 1977; 118: 226-8.
19. Antonarakis SE, Kazazian HH, Gitshier J, Hutter P, de Moerloose P, Morris M. Molecular etiology of Factor VIII deficiency in Hemophilia A. In: Inhibitors to Coagulation Factors. Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC, eds. Plenum, New York, NY 1995; 19-34.
20. Reisner HM, Clark A, Levin L. Immunogenetics of the Human Immune Response to Factor VIII. In: Inhibitors to Coagulation Factors. Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC, eds. Plenum, New York, NY 1995; 65-78.
21. Gilles JGG, Arnout J, Vermylen J, Saint-Rémy J-MR. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards non-functional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452-61.
22. Fulcher CA, De Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-80.
23. Scandella D, Mattingly M, De Graaf S, Fulcher CA. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 1989; 74: 1618-26.
24. Scandella D, Mahoney De Graaf S, Mattingly M, Roeder D, Timmons L, Fulcher CA. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. Proc Natl Acad Sci USA 1988; 85: 6152-6.
25. Weigle WO. The immune response of rabbits tolerant to bovine serum albumin to the injection of other heterologous serum albumins. J Immunol 1961; 114: 111-22.
26. Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Ann Rev Immunol 1990; 8: 579-621.
27. Wacker WB, Donoso LA, Kalsow CM, Yankeelov JA Jr, Organisciak DT. Isolation, characterization, and localization of a soluble uveitopathogenic antigen from bovine retina. J Immunol 1977; 119: 1949-58.
28. Pearson CM. Experimental joint disease: Observations on adjuvant induced arthritis. J Chron Dis 1963; 16: 863-74.
29. Pittman DD, Alderman EM, Tomkinson KN, Wang IH, Giles AR, Kaufman RJ. Biochemical, immunological and in vivo functional characterization of B-domain-deleted Factor VIII. Blood 1993; 81: 2925-35.